Evaluation of the initiation of erythropoiesis-stimulating agents in chronic kidney disease patients in a local setting

Ms. Judy LAM C.K.(1)(2) Ms. Helena TSE K.Y.(1)(2), Mr. Andrew WOO W.C.(1)(2), Dr. Jennifer YU(1)

(1)School of Pharmacy, Faculty of Medicine, the Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. (2)Pharmacy Department, Pamela Youde Nethersole Eastern Hospital (PYNEH), Hong Kong.

Keywords:
erythropoiesis-stimulating agents
chronic kidney disease

Introduction

Objectives
The aim of the current study is to evaluate whether the initiation of erythropoiesis-stimulating agents (ESAs) in dialysis patients in a local setting complies with international clinical guidelines.

Methodology
This is a retrospective drug use evaluation study on the initiation of ESA in chronic kidney disease (CKD) patients followed up at PYNEH for the compliance with the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline. Patients who had ESA initiated between 1st January 2008 and 31st August 2012, and aged 18 or above at the time of initiation, became the candidates of this DUE. The initial anemia assessment, subsequent haemoglobin (Hb) and iron status monitoring frequency were evaluated using data from electronic patient record.

Result
This is a retrospective drug use evaluation study on the initiation of ESA in chronic kidney disease (CKD) patients followed up at PYNEH for the compliance with the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline. Patients who had ESA initiated between 1st January 2008 and 31st August 2012, and aged 18 or above at the time of initiation, became the candidates of this DUE. The initial anemia assessment, subsequent haemoglobin (Hb) and iron status monitoring frequency were evaluated using data from electronic patient record.